Latest news with #StartEngine
Business Upturn
4 days ago
- Business
- Business Upturn
OUSIA Labs Launches Capital Raise on StartEngine to Democratize CO₂ Botanical Extraction for the Home
Loveland, Colorado, June 03, 2025 (GLOBE NEWSWIRE) — OUSIA Labs, a pioneering natural products technology company, has officially launched its capital raise on StartEngine, aiming to raise $128,000 in its first phase. The company is offering early investors a stake in what could be the future of at-home botanical oil extraction, a lab-grade CO₂ system engineered into a compact consumer appliance. Advertisement OUSIA Labs Led by duo David and Gary Ross, OUSIA Labs was founded in 2020 with the mission of bringing pure, solvent-free extraction to everyday people. Now, with a patented appliance, pre-sold units in hand, and strategic partnerships with global distributors, the company is turning to equity crowdfunding to scale. 'We've been well vetted to get on StartEngine, and we're excited to invite investors to join this next chapter,' said David, COO and co-inventor. 'Our early traction shows the appetite for natural, at-home wellness products made with transparency and purity.' The flagship product, the OUSIA Fountain, is one of the first compact CO₂ extraction systems designed for home use. Traditional CO₂ extraction methods, often used in commercial labs, are generally cost-prohibitive and technically complex for everyday consumers. OUSIA has changed that by delivering a safe, affordable, and plug-and-play appliance for personal use. From essential oils and culinary extracts to DIY cosmetics and botanical tinctures, the OUSIA Fountain empowers consumers to control the purity, potency, and origin of their ingredients. For example, rosemary extract, which typically sells for maybe $30 for just 15ml of a diluted product, can be made for a fraction of the price using fresh rosemary. OUSIA's device yields high-purity oils with no need for harmful solvents or additives. 'The health-conscious consumer is growing more aware of what goes into their food and wellness products,' said David. 'CO₂ extraction is the gold standard for purity, and we've made it accessible in a way that's never been done before.' To date, over a hundred units have been pre-sold, and the company is actively shipping. OUSIA's technology has attracted interest from global distributors and culinary innovators, including those in the DIY soda and sous-vide industries, who value precise, potent, and controllable botanical flavoring. OUSIA operates in the $7.72 billion botanical extraction market, but the broader natural products segment, including gourmet food, wellness, cosmetics, and DIY tinctures, is approaching $11.63 billion globally. Use cases fall into three main consumer categories: culinary & beverages, cosmetics & bath, and wellness & tinctures. Early customers include artisan producers, influencers, and small businesses, such as a lavender farmer in California who uses the OUSIA Fountain to create pure oils for soap-making. In parallel, food tech companies are integrating the appliance into slow-cooking systems like sous-vide to create consistent, chef-grade herbal infusions. OUSIA Labs is currently raising $128,000 in its first round on StartEngine, a move that positions the company for deeper marketing and broader reach through the platform's venture portfolio. StartEngine investors eligible for the Venture Club will receive a 10% bonus in shares, adding further incentive for early support. For example, a $556 investment would yield 110 shares rather than 100, enhancing value for early backers. Additional loyalty and time-based bonuses may also apply, offering multiple ways for investors to gain preferred access and equity advantages. 'Anyone passionate about clean living, health and wellness, or small appliances has the opportunity to be part of a technology that's changing the way we interact with botanicals,' David concluded. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax situation. Media Contact Name: Conal Rosanbaulm Email: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
4 days ago
- Business
- Yahoo
OUSIA Labs Launches Capital Raise on StartEngine to Democratize CO₂ Botanical Extraction for the Home
CO₂ based botanical extraction appliance for consumers, OUSIA Labs, seeks the first phase of funding on StartEngine. Loveland, Colorado, June 03, 2025 (GLOBE NEWSWIRE) -- OUSIA Labs, a pioneering natural products technology company, has officially launched its capital raise on StartEngine, aiming to raise $128,000 in its first phase. The company is offering early investors a stake in what could be the future of at-home botanical oil extraction, a lab-grade CO₂ system engineered into a compact consumer appliance. OUSIA Labs Led by duo David and Gary Ross, OUSIA Labs was founded in 2020 with the mission of bringing pure, solvent-free extraction to everyday people. Now, with a patented appliance, pre-sold units in hand, and strategic partnerships with global distributors, the company is turning to equity crowdfunding to scale. 'We've been well vetted to get on StartEngine, and we're excited to invite investors to join this next chapter,' said David, COO and co-inventor. 'Our early traction shows the appetite for natural, at-home wellness products made with transparency and purity.' The flagship product, the OUSIA Fountain, is one of the first compact CO₂ extraction systems designed for home use. Traditional CO₂ extraction methods, often used in commercial labs, are generally cost-prohibitive and technically complex for everyday consumers. OUSIA has changed that by delivering a safe, affordable, and plug-and-play appliance for personal use. From essential oils and culinary extracts to DIY cosmetics and botanical tinctures, the OUSIA Fountain empowers consumers to control the purity, potency, and origin of their ingredients. For example, rosemary extract, which typically sells for maybe $30 for just 15ml of a diluted product, can be made for a fraction of the price using fresh rosemary. OUSIA's device yields high-purity oils with no need for harmful solvents or additives. 'The health-conscious consumer is growing more aware of what goes into their food and wellness products,' said David. 'CO₂ extraction is the gold standard for purity, and we've made it accessible in a way that's never been done before.' To date, over a hundred units have been pre-sold, and the company is actively shipping. OUSIA's technology has attracted interest from global distributors and culinary innovators, including those in the DIY soda and sous-vide industries, who value precise, potent, and controllable botanical flavoring. OUSIA operates in the $7.72 billion botanical extraction market, but the broader natural products segment, including gourmet food, wellness, cosmetics, and DIY tinctures, is approaching $11.63 billion globally. Use cases fall into three main consumer categories: culinary & beverages, cosmetics & bath, and wellness & tinctures. Early customers include artisan producers, influencers, and small businesses, such as a lavender farmer in California who uses the OUSIA Fountain to create pure oils for soap-making. In parallel, food tech companies are integrating the appliance into slow-cooking systems like sous-vide to create consistent, chef-grade herbal infusions. OUSIA Labs is currently raising $128,000 in its first round on StartEngine, a move that positions the company for deeper marketing and broader reach through the platform's venture portfolio. StartEngine investors eligible for the Venture Club will receive a 10% bonus in shares, adding further incentive for early support. For example, a $556 investment would yield 110 shares rather than 100, enhancing value for early backers. Additional loyalty and time-based bonuses may also apply, offering multiple ways for investors to gain preferred access and equity advantages. 'Anyone passionate about clean living, health and wellness, or small appliances has the opportunity to be part of a technology that's changing the way we interact with botanicals,' David concluded. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax situation. Media Contact Name: Conal Rosanbaulm Email: conal@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
AsyncHealth launches Crowdfunding Campaign on StartEngine using Artificial Intelligence to Revolutionize Mental Health Care
AsyncHealth has a clinician-built platform that uses AI to streamline the delivery of mental health care, increasing patient access and saving clinician time. SACRAMENTO, Calif., May 28, 2025 /PRNewswire/ -- AsyncHealth, a company that has developed a cutting-edge platform that leverages AI agents and scribes to streamline mental health care, is excited to announce the launch of its crowdfunding campaign on StartEngine. This campaign aims to raise funds to further develop and expand AsyncHealth's innovative solutions, making mental health care more accessible, efficient, and effective for both providers and patients. Async is a clinician-built platform that uses AI to streamline the delivery of mental health care. The platform's virtual interviewer assistants handle patient intake, triage, and progress monitoring, while AI scribes generate the required documentation, saving providers more than 50% of their time. This enables better care, less burnout, and greater flexibility for clinicians. For patients, AsyncHealth's asynchronous approach removes the barriers of traditional appointment scheduling, improves access to care, and enhances continuity of care. "We are thrilled to launch our crowdfunding campaign on StartEngine," said Peter Yellowlees, MD, CEO of AsyncHealth. "Our mission is to revolutionize mental health care by leveraging AI to create a more responsive and supportive care experience. With the support of our investors, we can scale our impact and make a substantial difference in the lives of both providers and patients." AsyncHealth has already raised nearly $200,000 in the first two weeks of the campaign, demonstrating strong support from mental health providers, patients and early supporters who believe in the company's mission. The funds raised will be used to further develop the platform, enhance its features, and expand its reach to more providers and patients. Potential investors can learn more about the campaign and invest in AsyncHealth by visiting the StartEngine campaign page: The campaign offers various investment tiers and perks for investors, making it an attractive opportunity for those looking to support innovative solutions in mental health care. In addition to the crowdfunding campaign, AsyncHealth will be hosting a series of interactive webinars where the team will share more about the platform, growth plans, and answer questions live. Interested individuals can register for the webinars or reach out to the team at founders@ for more information. AsyncHealth's leadership team includes internationally recognized telepsychiatry expert Peter Yellowlees, MD, co-founder of a telehealth company sold to a Fortune 500 firm, and former president of the American Telemedicine Association; Steven Chan, MD, MBA, CTO, a triple board-certified psychiatrist and former Microsoft engineer with deep expertise in health informatics; and Robert Gregoire, CBO, a serial entrepreneur and corporate executive with extensive experience in developing and exiting successful ventures. For more information about AsyncHealth ( and the crowdfunding campaign, please visit Disclaimer: This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. About Asynchealth Inc AsyncHealth launches crowdfunding campaign on StartEngine using AI to revolutionize mental health care Press Contact:Peter Yellowlees916-833-1874http:// View original content to download multimedia: SOURCE Asynchealth Inc Sign in to access your portfolio
Globe and Mail
30-04-2025
- Business
- Globe and Mail
FrontFundr Shatters Records, Releases 2024 Community Capital Report
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- FrontFundr, Canada's leading equity crowdfunding platform, today unveiled its 2024 Community Capital Report, showcasing a groundbreaking year that signals a major shift in Canada's private investing landscape. In 2024, the platform facilitated an impressive $68.3 million in capital across 66 successful campaigns, more than doubling the amount raised in 2023. This milestone marks a turning point in how Canadians are engaging with private markets and demonstrates the growing appeal of equity crowdfunding. Since its launch in 2015 through December 31, 2024, FrontFundr facilitated over $258 million in capital through nearly 28,000 investments through its online platform, solidifying its leadership in Canada's fast-growing equity crowdfunding sector. The platform now holds an impressive 93% market share under the National Instrument 45-110 Startup Crowdfunding (prospectus) Exemption, underscoring its pivotal role in democratizing access to capital for early-stage companies. Noteworthy campaigns in 2024 include Blossom Social, which raised $1.35 million in just 3.5 days, and Edison Motors, which secured $2.4 million in 2024 alone—setting new benchmarks for crowdfunding success in Canada. "Equity crowdfunding is no longer a niche alternative; it's becoming a central component of how Canadians invest in the future they want to build," said Peter-Paul Van Hoeken, Founder and CEO of FrontFundr. "Our growth reflects a broader movement toward the retailization of private markets, empowering the public to participate, providing emerging companies better access to capital, and creating a more inclusive financial system." Key highlights from the 2024 report include: Investor Growth: Women now represent 26% of investors; individuals aged 30–39 were the most active investors. Sector Leadership: Finance led with over $55 million raised, followed by strong growth in technology, cleantech manufacturing, and food & beverage. Regional Highlights: Ontario led with $35.6 million raised, followed by British Columbia and a resurgent Alberta, with notable growth across the Prairies. Strong Portfolio Performance: 87% of FrontFundr-funded companies remain active, with 13.7% achieving liquidity events—including notable 2024 exits from Hempalta and Liquid Wind. Platform Innovation: New features like a redesigned investment workflow, the launch of FrontFundr Elite Circle, and a partnership with StartEngine offering access to U.S. AI deals fueled a 17% increase in average investment size and a 97% increase in new investors. Platform innovations—including a streamlined investment journey, the launch of FrontFundr Elite Circle, and a partnership with StartEngine to access U.S. Accredited Investor-only opportunities—helped boost average investment size by 17% and nearly double new investor sign-ups. 'This report captures a pivotal moment for Canada's private markets,' said Trieste Reading, VP of Growth at FrontFundr. '2024 wasn't just a breakout year for FrontFundr — it signaled a broader shift in how Canadians think about investing and ownership. Canadians are stepping up to back the businesses and causes they care about — and that's changing the future of finance.' The release of the 2024 Community Capital Report comes at a time of growing global momentum to expand access to private markets. This shift was underscored by BlackRock CEO Larry Fink's 2025 annual letter, which called for democratizing private market opportunities so everyday investors—not just the wealthy—can benefit from the returns of economic growth. As FrontFundr approaches its 10th anniversary in 2025, the platform remains steadfast in its mission to open doors for all Canadians to invest in businesses that reflect their values and shape the future. The full Community Capital Report 2024 is available at About FrontFundr FrontFundr is Canada's leading private markets investing platform, empowering startups and growth-stage companies to raise capital from their biggest supporters—everyday Canadians. Since 2015, FrontFundr has enabled thousands of investors to access vetted investment opportunities in private companies, from promising startups to established growth businesses. Whether you're a seasoned investor or making your first-ever investment, FrontFundr makes it easy to participate in building the future of innovation and entrepreneurship in Canada. Learn more at
Yahoo
05-04-2025
- Business
- Yahoo
Berkshire Biomedical to Host Live COPA™ Technology Webinar as StartEngine Campaign Nears Close
Exclusive opportunity for investors to see breakthrough medication delivery system in action Dallas, TX , April 05, 2025 (GLOBE NEWSWIRE) -- Berkshire Biomedical invites the public and prospective investors to an exclusive webinar showcasing its proprietary COPA™ technology, 'How COPA™ Delivers the Right Medication to the Right Person, in the Right Amount, at the Right Time,' on Tuesday, April 8, 2025, at 1:30 PM virtual event comes as Berkshire's equity crowdfunding campaign on StartEngine enters its final stretch—offering a limited-time opportunity for investors to be part of the future of personalized medication management. Medication errors and non-adherence are a silent epidemic. COPA™—Controlled Oral Prescription Administration—is designed to change that. The system ensures that only an Authenticated Intended User™ (AIU™) can access a prescribed dose, using dual-biometric authentication via fingerprint and dentition. With real-time remote monitoring, smart reminders, and secure data-sharing, COPA™ is poised to redefine safety, control, and adherence in both pain management and opioid use disorder treatment. The live webinar will feature: A live demonstration of COPA™ and its dual-biometric authentication in action Videos and visuals illustrating its core technologies A deep dive into how COPA™ supports patients, providers, and caregivers A look into COPA's robust U.S. and international intellectual property portfolio An open Q&A session with Berkshire's leadership team This is a unique opportunity to experience the COPA™ system firsthand and engage directly with Berkshire's leadership team in a live Q&A. The webinar also coincides with the closing phase of Berkshire's StartEngine campaign, giving potential investors a final opportunity to learn more about the company and its mission. Register now to attendAbout Berkshire Biomedical Corporation Berkshire Biomedical Corporation is a privately held medical device company. Berkshire is pioneering the use of biometric technologies, combined with encrypted HIPAA compliant cloud-based and healthcare provider-enabled remote management systems, to provide precise and accurate personalized medication delivery to only the Authenticated Intended User (AIU). The Company's lead product under development, the Computerized Oral Prescription Administration System (COPA), is a hand-held, automated, personalized oral liquid dispensing system designed and intended to deliver controlled and non-controlled liquid oral medications to only the AIU upon confirmation of dual biometric identification (fingerprint and dentition). Upon receiving regulatory authorization, the Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of oral liquid medication methadone, for Medication Use for Opioid Use Disorder treatment and subsequently for the delivery of controlled medications for the treatment of pain, as those patients have the greatest need for the benefits of COPA's features. As previously announced, the Company is developing COPA with the support of a $2.0 million Fast-Track Small Business Innovation Research grant from the National Institute of Drug Abuse of the National Institutes of Health under award number R44DA057185. In the future, the Company will look to expand COPA usage into a broader set of drug therapeutics, possible clinical applications, as well as with companies that utilize and commercialize data analytics provided by electronic devices to improve outcomes and reduce risk. The COPA System is currently under development, has NOT been reviewed by the U.S. Food and Drug Administration and is not available for commercial John Timberlake President, CEO, CFO, and Director Berkshire Biomedical info at
